Medscape Diabetes & EndocrinologyCOMMENTARY Kevin Fernando, MBChB, MSc Diabetes, BSc DISCLOSURES | June 03, 2024 There has been much hyperbole since the presentation of results from the SELECT cardiovascular outcomes trial (CVOT) at this year’s European Congress on Obesity, which led many to herald semaglutide as the “new statin.” In the SELECT CVOT, participants with...